ROS activated prodrug for ALDH overexpressed cancer stem cells

Miae Won; Ji Hyeon Kim; Myung Sun Ji; Jong Seung Kim

doi:10.1039/d1cc05573a

ROS activated prodrug for ALDH overexpressed cancer stem cells

Miae Won, Ji Hyeon Kim, Myung Sun Ji, Jong Seung Kim

Research output: Contribution to journal › Article › peer-review

2 Citations (Scopus)

Abstract

Aldehyde dehydrogenase (ALDH), a cancer stem cell biomarker, is related to drug resistance. Co-treatment of anti-cancer drug (CPT) and ALDH inhibitor (DEAB) can overcome the drug resistance of cancer stem cells (CSCs) and finally cure cancers without relapse. We herein introduce a prodrug (DE-CPT) - consisting of 1,3-oxathiolane as an ROS responsive scaffold, and an aldehyde protecting group of DEAB - to deliver the CPT and DEAB upon reaction with ROS. From tests of the sphere-forming ability and CSC marker subpopulation, we found that DE-CPT efficiently decreases the CSCs population and kills the cancer cells.

Original language	English
Pages (from-to)	72-75
Number of pages	4
Journal	Chemical Communications
Volume	58
Issue number	1
DOIs	https://doi.org/10.1039/d1cc05573a
Publication status	Published - 2022 Jan 4

ASJC Scopus subject areas

Catalysis
Electronic, Optical and Magnetic Materials
Ceramics and Composites
Chemistry(all)
Surfaces, Coatings and Films
Metals and Alloys
Materials Chemistry

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1039/d1cc05573a

Cite this

@article{f5cfb0a7599c4546a4a8d1865fe25b3c,

title = "ROS activated prodrug for ALDH overexpressed cancer stem cells",

abstract = "Aldehyde dehydrogenase (ALDH), a cancer stem cell biomarker, is related to drug resistance. Co-treatment of anti-cancer drug (CPT) and ALDH inhibitor (DEAB) can overcome the drug resistance of cancer stem cells (CSCs) and finally cure cancers without relapse. We herein introduce a prodrug (DE-CPT) - consisting of 1,3-oxathiolane as an ROS responsive scaffold, and an aldehyde protecting group of DEAB - to deliver the CPT and DEAB upon reaction with ROS. From tests of the sphere-forming ability and CSC marker subpopulation, we found that DE-CPT efficiently decreases the CSCs population and kills the cancer cells.",

author = "Miae Won and Kim, {Ji Hyeon} and Ji, {Myung Sun} and Kim, {Jong Seung}",

note = "Funding Information: This work was supported by the National Research Foundation of Korea (NRF) funded by the Ministry of Science and ICT (CRI project no. 2018R1A3B1052702 and no. 2019M3E5D1A01068998, J. S. K.) and the global PhD fellowship (GPF) program (no. 2019H1A2A1074096, J. H. K.), funded by the Ministry of Education. This research was supported by the Korea University Graduate School Junior Fellow Research Grant (J. H. K). Publisher Copyright: {\textcopyright} The Royal Society of Chemistry 2021.",

year = "2022",

month = jan,

day = "4",

doi = "10.1039/d1cc05573a",

language = "English",

volume = "58",

pages = "72--75",

journal = "Chemical Communications",

issn = "1359-7345",

publisher = "Royal Society of Chemistry",

number = "1",

}

TY - JOUR

T1 - ROS activated prodrug for ALDH overexpressed cancer stem cells

AU - Won, Miae

AU - Kim, Ji Hyeon

AU - Ji, Myung Sun

AU - Kim, Jong Seung

N1 - Funding Information: This work was supported by the National Research Foundation of Korea (NRF) funded by the Ministry of Science and ICT (CRI project no. 2018R1A3B1052702 and no. 2019M3E5D1A01068998, J. S. K.) and the global PhD fellowship (GPF) program (no. 2019H1A2A1074096, J. H. K.), funded by the Ministry of Education. This research was supported by the Korea University Graduate School Junior Fellow Research Grant (J. H. K). Publisher Copyright: © The Royal Society of Chemistry 2021.

PY - 2022/1/4

Y1 - 2022/1/4

N2 - Aldehyde dehydrogenase (ALDH), a cancer stem cell biomarker, is related to drug resistance. Co-treatment of anti-cancer drug (CPT) and ALDH inhibitor (DEAB) can overcome the drug resistance of cancer stem cells (CSCs) and finally cure cancers without relapse. We herein introduce a prodrug (DE-CPT) - consisting of 1,3-oxathiolane as an ROS responsive scaffold, and an aldehyde protecting group of DEAB - to deliver the CPT and DEAB upon reaction with ROS. From tests of the sphere-forming ability and CSC marker subpopulation, we found that DE-CPT efficiently decreases the CSCs population and kills the cancer cells.

AB - Aldehyde dehydrogenase (ALDH), a cancer stem cell biomarker, is related to drug resistance. Co-treatment of anti-cancer drug (CPT) and ALDH inhibitor (DEAB) can overcome the drug resistance of cancer stem cells (CSCs) and finally cure cancers without relapse. We herein introduce a prodrug (DE-CPT) - consisting of 1,3-oxathiolane as an ROS responsive scaffold, and an aldehyde protecting group of DEAB - to deliver the CPT and DEAB upon reaction with ROS. From tests of the sphere-forming ability and CSC marker subpopulation, we found that DE-CPT efficiently decreases the CSCs population and kills the cancer cells.

UR - http://www.scopus.com/inward/record.url?scp=85121707538&partnerID=8YFLogxK

U2 - 10.1039/d1cc05573a

DO - 10.1039/d1cc05573a

M3 - Article

C2 - 34874378

AN - SCOPUS:85121707538

VL - 58

SP - 72

EP - 75

JO - Chemical Communications

JF - Chemical Communications

SN - 1359-7345

IS - 1

ER -

ROS activated prodrug for ALDH overexpressed cancer stem cells

Abstract

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this